Lessons from patient safety to accelerate healthcare decarbonization.

J Hosp Med

Department of Anesthesiology, Yale School of Medicine, New Haven, Connecticut, USA.

Published: November 2024

Download full-text PDF

Source
http://dx.doi.org/10.1002/jhm.13493DOI Listing

Publication Analysis

Top Keywords

lessons patient
4
patient safety
4
safety accelerate
4
accelerate healthcare
4
healthcare decarbonization
4
lessons
1
safety
1
accelerate
1
healthcare
1
decarbonization
1

Similar Publications

"Just Be Relentless," Lessons Learned from In-Hospital Addiction Consult Service Implementation.

J Gen Intern Med

January 2025

Section of Addiction Medicine in Division of General Internal Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.

Background: Hospitalization is a "reachable" moment to engage people in addiction care. Addiction consult services (ACSs) have been shown to improve outcomes for hospitalized patients with substance use disorders (SUDs). Despite this, most hospital systems do not provide hospital-based addiction care or have an ACS.

View Article and Find Full Text PDF

Objectives: Buprenorphine has recently emerged as a prehospital treatment for opioid use disorder. Limited data exist regarding the implementation of prehospital buprenorphine programs. Our objective was to describe the development, deployment, lessons learned, and ongoing evolution of the Wake County EMS buprenorphine program using data from the first year following implementation.

View Article and Find Full Text PDF

Background: Amyloid PET imaging is an established diagnostic tool for Alzheimer's disease, but its successful integration into clinical practice requires a comprehensive understanding of its impact on patients and the healthcare system. In 2022, the coverage with evidence development (CED) ENABLE study has been approved by the German Federal Joint Committee (trial registration: DRKS00030839). The study is scheduled to start in early 2024.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Merck & Co., Inc., Rahway, NJ, USA.

Background: A lesson of the recent progress in Alzheimer's Disease therapy is that biomarker-driven trials will be crucial to demonstrating efficacy in the clinic. Many studies have demonstrated the potential predictive power of fluid and imaging biomarkers in guiding patient selection and continued progress of precision medicine approaches will demand development of multi-dimensional biomarker arrays. However, correlations between candidate biomarkers change non-linearly with time, requiring methodologies to align biomarkers across a common disease timescale (time from amyloid positivity; TFAP).

View Article and Find Full Text PDF

Background: The expected seasonal recurrence of (new variants of) COVID-19 and the emergence of other airborne infectious diseases underscore the need for a sustainable healthcare preparedness strategy. It is particularly essential to ensure equitable access to healthcare for individuals with chronic diseases, including dementia and Parkinson's Disease. Moreover, it is vital to provide clinicians and researchers in the neurodegenerative disease fields with resources and infrastructure to ensure continuity of their work, even during a pandemic.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!